High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC

	High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
	Fan, Y.
刊名	JOURNAL OF THORACIC ONCOLOGY
	2022-09-01
卷号	17
关键词	NSCLC EGFR TKI Brain Metastases
ISSN号	1556-0864
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000858678101180
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129809]
专题	中国科学院合肥物质科学研究院
作者单位	Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Fan, Y.. High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC[J]. JOURNAL OF THORACIC ONCOLOGY,2022,17.
APA	Fan, Y..(2022).High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC.JOURNAL OF THORACIC ONCOLOGY,17.
MLA	Fan, Y.."High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC".JOURNAL OF THORACIC ONCOLOGY 17(2022).